MX394051B - Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo - Google Patents
Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismoInfo
- Publication number
- MX394051B MX394051B MX2021000773A MX2021000773A MX394051B MX 394051 B MX394051 B MX 394051B MX 2021000773 A MX2021000773 A MX 2021000773A MX 2021000773 A MX2021000773 A MX 2021000773A MX 394051 B MX394051 B MX 394051B
- Authority
- MX
- Mexico
- Prior art keywords
- hepe
- compositions
- methods
- same
- relates
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269280P | 2015-12-18 | 2015-12-18 | |
| PCT/IB2016/001878 WO2017103671A1 (en) | 2015-12-18 | 2016-12-19 | Compositions comprising 15-hepe and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2021000773A MX2021000773A (es) | 2022-07-19 |
| MX394051B true MX394051B (es) | 2025-03-24 |
Family
ID=57995240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000773A MX394051B (es) | 2015-12-18 | 2016-12-19 | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo |
| MX2018007390A MX379262B (es) | 2015-12-18 | 2016-12-19 | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007390A MX379262B (es) | 2015-12-18 | 2016-12-19 | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9855238B2 (enExample) |
| EP (2) | EP3389647B1 (enExample) |
| JP (4) | JP2018537513A (enExample) |
| KR (6) | KR20180094516A (enExample) |
| CN (2) | CN108697680A (enExample) |
| AR (2) | AR107143A1 (enExample) |
| AU (4) | AU2016370626B2 (enExample) |
| BR (1) | BR122023026625A2 (enExample) |
| CA (2) | CA3129008A1 (enExample) |
| ES (1) | ES2948444T3 (enExample) |
| IL (3) | IL318963A (enExample) |
| MX (2) | MX394051B (enExample) |
| NZ (1) | NZ744323A (enExample) |
| PH (1) | PH12018501279A1 (enExample) |
| RU (2) | RU2737089C2 (enExample) |
| SG (1) | SG11201805149XA (enExample) |
| WO (1) | WO2017103671A1 (enExample) |
| ZA (2) | ZA201804779B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| CN105899485B (zh) | 2013-11-15 | 2018-10-19 | 尊严科学有限公司 | 多不饱和羟基脂肪酸的药学上可接受的盐 |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| CN113896628A (zh) | 2015-05-13 | 2022-01-07 | Ds生物制药有限公司 | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
| EP3861995A1 (en) | 2015-07-21 | 2021-08-11 | Affimune Limited | Compositions comprising 15-hepe for use in treating or preventing neurologic disease |
| KR20180094516A (ko) | 2015-12-18 | 2018-08-23 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
| CN113116878A (zh) * | 2020-01-10 | 2021-07-16 | 南京大学 | 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US11622495B2 (en) | 2021-06-01 | 2023-04-11 | Gint Co., Ltd. | Method of automatically combining farm vehicle and work machine and farm vehicle |
| CN113855659B (zh) * | 2021-11-24 | 2022-12-23 | 中国人民解放军东部战区总医院 | 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| BR9405620A (pt) | 1993-10-01 | 1999-09-08 | Scherer Corp R P | Cápsula de gelatina contendo fragrncia, e, processo para sua preparação |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| ATE504557T1 (de) | 2000-02-16 | 2011-04-15 | Brigham & Womens Hospital | Aspirin-ausgelöste lipidmediatoren |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| US20020198177A1 (en) | 2001-05-30 | 2002-12-26 | Horrobin David Frederick | Coenzyme Q and EPA |
| WO2004048497A1 (ja) | 2002-11-22 | 2004-06-10 | Nippon Suisan Kaisha, Ltd. | 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物 |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| WO2005063231A2 (en) | 2003-12-31 | 2005-07-14 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof |
| US20050239889A1 (en) | 2004-04-26 | 2005-10-27 | Jean Gosselin | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration |
| CA2572344A1 (en) | 2004-07-01 | 2006-01-19 | Schepens Eye Research | Compositions and methods for treating eye disorders and conditions |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| JP5504405B2 (ja) * | 2005-06-10 | 2014-05-28 | 国立大学法人山口大学 | 血管病予防に効果を有する食品組成物 |
| WO2008021192A2 (en) | 2006-08-08 | 2008-02-21 | Lipomics Technologies, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| US20110105510A1 (en) | 2008-06-17 | 2011-05-05 | Hiroshi Ishikawa | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| JP2010229099A (ja) * | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| EP2433630A4 (en) * | 2009-05-22 | 2014-01-08 | Mochida Pharm Co Ltd | SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3 |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| US10154977B2 (en) | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| SG11201401629XA (en) | 2011-10-19 | 2014-05-29 | Dignity Sciences Ltd | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| JP2015500639A (ja) | 2011-11-29 | 2015-01-08 | ディグニティ サイエンシス リミテッド | ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法 |
| CN104321055A (zh) | 2012-01-06 | 2015-01-28 | 翁特拉制药公司 | 游离酸形式的ω-3多不饱和脂肪酸的富含dpa组合物 |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| IN2014DN08449A (enExample) * | 2012-03-30 | 2015-05-08 | Sancilio & Company Inc | |
| US20150079164A1 (en) | 2012-04-04 | 2015-03-19 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
| EP4205546A1 (en) * | 2012-05-10 | 2023-07-05 | Solutex NA LLC | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
| GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| ES2841344T3 (es) * | 2013-07-18 | 2021-07-08 | Mochida Pharm Co Ltd | Composición autoemulsionante de ácidos grasos omega-3 |
| CN105899485B (zh) * | 2013-11-15 | 2018-10-19 | 尊严科学有限公司 | 多不饱和羟基脂肪酸的药学上可接受的盐 |
| US20150196521A1 (en) * | 2014-01-10 | 2015-07-16 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| CN113893240A (zh) * | 2015-01-16 | 2022-01-07 | 艾菲穆恩有限公司 | 包含15-hepe的组合物和其使用方法 |
| CN113896628A (zh) | 2015-05-13 | 2022-01-07 | Ds生物制药有限公司 | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
| EP3861995A1 (en) * | 2015-07-21 | 2021-08-11 | Affimune Limited | Compositions comprising 15-hepe for use in treating or preventing neurologic disease |
| KR20180094516A (ko) * | 2015-12-18 | 2018-08-23 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
-
2016
- 2016-12-19 KR KR1020187020457A patent/KR20180094516A/ko not_active Ceased
- 2016-12-19 KR KR1020257027779A patent/KR20250130433A/ko active Pending
- 2016-12-19 AR ARP160103915A patent/AR107143A1/es not_active Application Discontinuation
- 2016-12-19 IL IL318963A patent/IL318963A/en unknown
- 2016-12-19 BR BR122023026625-0A patent/BR122023026625A2/pt not_active Application Discontinuation
- 2016-12-19 CA CA3129008A patent/CA3129008A1/en active Pending
- 2016-12-19 RU RU2018126361A patent/RU2737089C2/ru active
- 2016-12-19 US US15/383,889 patent/US9855238B2/en active Active
- 2016-12-19 CN CN201680082030.9A patent/CN108697680A/zh active Pending
- 2016-12-19 WO PCT/IB2016/001878 patent/WO2017103671A1/en not_active Ceased
- 2016-12-19 EP EP16834282.2A patent/EP3389647B1/en active Active
- 2016-12-19 KR KR1020227008483A patent/KR20220038818A/ko not_active Ceased
- 2016-12-19 NZ NZ744323A patent/NZ744323A/en unknown
- 2016-12-19 KR KR1020247011532A patent/KR20240052856A/ko not_active Ceased
- 2016-12-19 RU RU2020137883A patent/RU2020137883A/ru unknown
- 2016-12-19 KR KR1020237010220A patent/KR20230047501A/ko not_active Ceased
- 2016-12-19 CA CA3008774A patent/CA3008774C/en active Active
- 2016-12-19 KR KR1020207013456A patent/KR20200055154A/ko not_active Ceased
- 2016-12-19 MX MX2021000773A patent/MX394051B/es unknown
- 2016-12-19 SG SG11201805149XA patent/SG11201805149XA/en unknown
- 2016-12-19 CN CN202110567290.8A patent/CN113230244A/zh active Pending
- 2016-12-19 MX MX2018007390A patent/MX379262B/es unknown
- 2016-12-19 AU AU2016370626A patent/AU2016370626B2/en active Active
- 2016-12-19 ES ES16834282T patent/ES2948444T3/es active Active
- 2016-12-19 JP JP2018531629A patent/JP2018537513A/ja active Pending
- 2016-12-19 IL IL294736A patent/IL294736A/en unknown
- 2016-12-19 EP EP23158607.4A patent/EP4218736A3/en active Pending
-
2017
- 2017-12-14 US US15/841,363 patent/US10231945B2/en active Active
-
2018
- 2018-06-06 IL IL259846A patent/IL259846A/en unknown
- 2018-06-14 PH PH12018501279A patent/PH12018501279A1/en unknown
- 2018-07-17 ZA ZA2018/04779A patent/ZA201804779B/en unknown
-
2019
- 2019-01-31 US US16/263,486 patent/US20190224154A1/en not_active Abandoned
- 2019-11-27 JP JP2019214063A patent/JP2020063259A/ja active Pending
-
2020
- 2020-11-11 AU AU2020267224A patent/AU2020267224B2/en active Active
-
2021
- 2021-07-15 ZA ZA2021/04969A patent/ZA202104969B/en unknown
- 2021-07-19 JP JP2021118532A patent/JP2021178840A/ja active Pending
-
2022
- 2022-05-20 US US17/750,262 patent/US12274685B2/en active Active
- 2022-12-23 AU AU2022291628A patent/AU2022291628B2/en active Active
-
2023
- 2023-07-21 JP JP2023118782A patent/JP2023153863A/ja active Pending
-
2024
- 2024-11-04 AR ARP240103022A patent/AR134220A2/es unknown
-
2025
- 2025-03-05 AU AU2025201593A patent/AU2025201593A1/en active Pending
- 2025-03-19 US US19/083,602 patent/US20250281442A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004557B (en) | Modulatory polynucleotides | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| ZA201902141B (en) | Acid-alpha glucosidase variants and uses thereof | |
| PH12018501378A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| PH12018500950B1 (en) | Subcutaneous formulations of anti-cd38 antibodies and their uses | |
| EP4620519A3 (en) | Methods and compositions relating to chondrisomes from blood products | |
| ZA201902140B (en) | Acid-alpha glucosidase variants and uses thereof | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| AU2015287674B2 (en) | Topical antiviral compositions and methods of using the same | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| ZA201902781B (en) | Compositions and methods for the treatment of xerostomia | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| EP3253211A4 (en) | Compositions and methods for treatment of edema | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| HK1255221A1 (zh) | 使用卡多曲组合物进行治疗的方法 | |
| MX383947B (es) | Composiciones de colágeno 7 y métodos para usar las mismas. | |
| PH12018501166B1 (en) | Concentrated gibberellin solution formulations | |
| MY182818A (en) | Compositions for the treatment of fibrosis and fibrosis-related conditions | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| DK3313207T3 (en) | Compositions and methods for the treatment of malnutrition |